Repurposing HIV Protease Inhibitors against West Nile Virus: Insights from Molecular Docking and Molecular Dynamics Simulations
Abstract
West Nile virus (WNV) is a neurotropic flavivirus lacking approved antiviral therapies. Here, we evaluated the repurposing potential of ten HIV protease inhibitors as inhibitors of the WNV NS2B-NS3 protease using molecular docking followed by molecular dynamics simulations. Structural, energetic, and interaction analyses revealed substantial differences in binding stability under dynamic conditions. Indinavir and Atazanavir consistently showed strong and stable interactions, low structural and positional fluctuations, persistent hydrogen bonding, and favorable binding free energies. In contrast, several inhibitors displayed transient binding despite favorable docking scores. These findings emphasize the importance of molecular dynamics in drug repurposing studies and identify Indinavir and Atazanavir as promising candidates for further experimental evaluation against WNV.
Read the paper
Related studies
- Chaos and quantum thermalization
- The Dalton quantum chemistry program system
- Quantum dots: synthesis, bioapplications, and toxicity
- Cord Blood Leptin and Adiponectin as Predictors of Adiposity in Children at 3 Years of Age: A Prospective Cohort Study
- A Guide to In Silico Drug Design
- Quantitative metabolomics by H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.